Alphatec Holdings Inc header image

Alphatec Holdings Inc

ATEC

Equity

ISIN null / Valor 33740497

NASDAQ (2026-04-24)
USD 10.90+6.76%

Alphatec Holdings Inc
UMushroom community rating:

star star star star star
5.00 1 votes No rating yet
NegativeNeutralPositive

About company

Alphatec Holdings Inc. is a medical technology company specializing in the design, development, and advancement of spinal surgery solutions. The company focuses on providing innovative products and procedures that aim to improve surgical outcomes and patient care in the field of spine surgery. Alphatec's portfolio includes a range of spinal implants and instruments designed to address various spinal disorders and conditions. The company leverages its expertise in surgical innovation to offer minimally invasive solutions that enhance the precision and effectiveness of spinal surgeries. Through continuous research and development, Alphatec aims to deliver cutting-edge technologies that meet the evolving needs of spine surgeons and their patients.

Summarized from source with an LLMView SourceSector: Finance

Latest Results (15.04.2026):

Alphatec Holdings, Inc. reported results for the quarter and year ended December 31, 2025 (Q4 2025). Total revenue for Q4 was $213 million and full-year 2025 revenue was $764 million (up ~25% year‑over‑year). The company showed marked margin and cash‑flow improvement with positive non‑GAAP net income and expanded adjusted EBITDA, while GAAP results remained a net loss for the quarter and full year. Management provided 2026 guidance of approximately $890 million in revenue and increased adjusted‑EBITDA guidance to about $134 million.

Revenue & Growth

Q4 2025 total revenue was $213M; full‑year 2025 revenue totaled $764M, a ~25% increase vs. 2024. Surgical revenue in Q4 was $190M, up 21% year‑over‑year.

Profitability & Margins

GAAP gross margin was ~70% (Q4 and FY). Non‑GAAP gross margin was ~70–71%. Adjusted EBITDA was $33.1M in Q4 (15.6% margin), $93.2M for full year (12.2% margin) — Q4 margin expanded ~390 basis points YoY. GAAP net loss was about $21.7M in Q4 and ~$143.4M for the full year; non‑GAAP net income was ~$9.4M in Q4 and ~$8.1M for the year.

Cash Flow & Balance Sheet

Ended 2025 with cash and cash equivalents of $160.8M. The company generated $8M of free cash flow in Q4 and $3M for the full year 2025. Short‑term debt increased (current short‑term debt ~$64.5M) and total liabilities remain elevated, but stockholders’ equity was positive at $12.4M at year‑end.

Operational & Commercial Momentum

Net new surgeon users rose 23% in Q4 and 20% for the full year, supporting durable case volume growth and the surgical revenue gains cited by management.

Product & Strategic Highlights

ATEC announced clearance and release of the Valence® intraoperative platform and highlighted continued proliferation of EOS Insight® as part of its procedural ecosystem driving adoption.

2026 Financial Outlook

For fiscal 2026 the company expects total revenue to approximate $890M (surgical ~$805M; EOS ~$85M), raised adjusted EBITDA guidance to ~ $134M (≈15% of revenue), and expects at least $20M of free cash flow for the year.

Summarized from source with an LLMView Source

Key figures

-4.39%1Y
-29.6%3Y
-34.8%5Y

Performance

57.3%1Y
63.6%3Y
61.1%5Y

Volatility

Market cap

1650 M

Market cap (USD)

Daily traded volume (Shares)

4,389,554

Daily traded volume (Shares)

1 day high/low

9.235 / 8.95

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

5.00

1 votes
Performance:
starstarstarstarstar
5.00
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
5.00
Nature:
starstarstarstarstar
5.00
David Cann
United Kingdom, 02 Nov 2025
star star star star star
Good Investment

EQUITIES OF THE SAME SECTOR

PEH Wertpapier AG
PEH Wertpapier AG PEH Wertpapier AG Valor: 972657
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.69%EUR 29.20
Societe Generale SA
Societe Generale SA Societe Generale SA Valor: 519928
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.79%EUR 69.16
Nuernberger Beteiligungs AG
Nuernberger Beteiligungs AG Nuernberger Beteiligungs AG Valor: 343295
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.40%EUR 124.00
SM Wirtschaftsberatungs AG
SM Wirtschaftsberatungs AG SM Wirtschaftsberatungs AG Valor: 19807071
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 4.88
IES Holdings Inc
IES Holdings Inc IES Holdings Inc Valor: 32699617
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.33%USD 599.80
EPIC Suisse Ltd
EPIC Suisse Ltd EPIC Suisse Ltd Valor: 51613168
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.14%CHF 88.40
Kite Realty Group Trust
Kite Realty Group Trust Kite Realty Group Trust Valor: 25008577
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.23%USD 25.97
Materion Corp
Materion Corp Materion Corp Valor: 12356209
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.44%USD 185.89
Lang & Schwarz Aktiengesellschaft
Lang & Schwarz Aktiengesellschaft Lang & Schwarz Aktiengesellschaft Valor: 2722632
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 27.80
Sofina SA
Sofina SA Sofina SA Valor: 836222
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.54%EUR 220.00